The Medicines Control Council (MCC) has granted patients with extremely drug-resistant tuberculosis (XDR-TB) access to Johnson & Johnson’s experimental drug bedaquiline, even though it has yet to be registered in South Africa....The death rate for patients with XDR-TB relying on current treatments is about 80%, according to Helen Cox, an epidemiologist with Doctors Without Borders in Cape Town...

Read article here